Table 4.
Analysis of neutralising antibodies (PRNT50; immunogenicity population)
ZyCoV-D (n=50) | Placebo (n=47) | |
---|---|---|
Day 0 | ||
GMT (95% CI) | 5·00 (5·00–5·00) | 5·00 (5·00–5·00) |
Day 56 | ||
GMT (95% CI) | 83·10 (50·70–136·20) | 28·64 (15·32–53·53) |
GMFR (95% CI) | 16·62 (10·14–27·24) | 5·73 (3·06–10·71) |
Day 84 | ||
GMT (95% CI) | 133·39 (86·88–204·81) | 26·99 (14·48–50·32) |
GMFR (95% CI) | 26·68 (17·38–40·96) | 5·40 (2·90–10·06) |
GMT=geometric mean titre. GMFR=geometric mean fold rise.